BioCentury
ARTICLE | Financial News

Clovis raises $275M in follow-on

July 10, 2015 2:46 AM UTC

Clovis Oncology Inc. (NASDAQ:CLVS) raised $275 million through the sale of 3.5 million shares at $78 in a follow-on underwritten by JPMorgan; Credit Suisse; Stifel; and Mizuho Securities. Clovis proposed the offering after market close Tuesday, when its share price was $85.76.

Last week, the company started submitting a rolling NDA to FDA for rociletinib ( AVL-301) to treat non-small cell lung cancer (NSCLC). Rociletinib is a small molecule that inhibits the T790M EGFR mutation and the initial activating EGFR mutations. ...